OpSens to Present at the Lytham Partners Fall 2021 Investor Conference – Tuesday, October 5, 2021, 9:30 AM
29 September 2021OPSENS TO PRESENT AT THE LYTHAM PARTNERS FALL 2021 INVESTOR CONFERENCE Presentation at 9:30 AM, Tuesday October 5, 2021 Quebec, Quebec, September 29, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a cardiology medical device company providing innovative product solutions based on its patented optical technology, announced today that it will present at…
OpSens Receives Approval from Health Canada to Initiate First In-Man Study For its New Guidewire For the TAVR Procedure
20 September 2021OPSENS RECEIVES APPROVAL FROM HEALTH CANADA TO INITIATE FIRST IN-MAN STUDY FOR ITS NEW GUIDEWIRE FOR THE TAVR PROCEDURE SAVVYWIRE, the first guidewire that aims to improve procedural efficiency and clinical outcomes for patients undergoing minimally invasive, Trans Aortic Valve Replacement (TAVR) Quebec, Quebec, September 20, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF)…
OpSens Appoints Lori Chmura to its Board of Directors
8 September 2021OpSens Appoints Lori Chmura to its Board of Directors Quebec City, Quebec, September 8, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, today announced the appointment of Lori Chmura to its board of Directors, effective September 8….